What Rallybio Corp does.

We are a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Our lead program, RLYB116, is a differentiated complement component 5 (“C5”) inhibitor with the potential to treat diseases of complement dysregulation. In addition, RLYB332, a long-acting matriptase-2 ("MTP-2") antibody for the treatment of diseases of iron overload, is currently in preclinical development.

On March 1, 2026, we entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Candid, a clinical-stage biotechnology company advancing a leading portfolio of T-cell engager ("TCE") therapeutics for autoimmune diseases, and Farmington Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Rallybio (“Merger Sub”). Upon the terms and subject to the satisfaction of the conditions described in the Merger Agreement, Merger Sub will be merged with and into Candid, with Candid surviving as a wholly owned subsidiary of Rallybio (the “Merger”). The Merger is intended to qualify as a tax-free reorganization for U.S. federal income tax purposes.

Revenue and profit, by fiscal year.

More on RLYB.

• Rallybio Corp summary
• Rallybio Corp financial statements
• Rallybio Corp key metrics
• Rallybio Corp health scores and style box
• Rallybio Corp earnings
• Rallybio Corp dividends
• Rallybio Corp valuation
• Rallybio Corp ownership and insiders
• Rallybio Corp peers

Figures from Rallybio Corp's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.